Intensity Therapeutics (INTS) Net Income towards Common Stockholders (2022 - 2026)

Intensity Therapeutics (INTS) has 5 years of Net Income towards Common Stockholders data on file, last reported at -$2.5 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 25.06% year-over-year to -$2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.1 million (up 25.99% YoY) and the FY2025 annual result came in at -$11.9 million, up 27.1% from the prior year.
• Net Income towards Common Stockholders advanced to -$2.5 million in Q1 2026, from -$3.1 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$1.3 million in Q1 2023 to a low of -$5.0 million in Q2 2023.
• A 5-year average of -$3.0 million and a median of -$2.9 million in 2025 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders sank 244.5% — and 2025, when it jumped 45.14%.
• Tracing INTS's Net Income towards Common Stockholders over 5 years: stood at -$1.5 million in 2022, then plunged by 110.0% to -$3.2 million in 2023, then decreased by 0.28% to -$3.2 million in 2024, then rose by 3.49% to -$3.1 million in 2025, then climbed by 17.1% to -$2.5 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$2.5 million (Q1 2026), -$3.1 million (Q4 2025), and -$2.8 million (Q3 2025), per Business Quant data.